Weekly Digest – July 2025 Weekly Digest – July 2025 08 July 2025: U.S. FDA grants orphan drug designation to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for gastric cancer The U.S. FDA granted orphan drug designation to Adcentrx Therapeutics ADC candidate […]
Weekly Digest – July 2025 Weekly Digest – July 2025 09 July 2025: Henlius receives global regulatory approvals for Phase 2 MRCT of its PD-L1 ADC HLX43 on NSCLC Henlius received regulatory approvals from China (NMPA), U.S. (FDA), Australia (TGA), […]
Weekly Digest – July 2025 Weekly Digest – July 2025 10 July 2025: PDS Biotech announces colorectal cancer cohort of Phase 2 clinical trial with PDS01 ADC met criteria for expansion to stage 2 following positive stage 1 results PDS […]
Weekly Digest – July 2025 Weekly Digest – July 2025 08 July 2025: Avenzo Therapeutics announces first patient dosed in Phase 1/2 clinical study of AVZO-1418, a potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate Avenzo Therapeutics has dosed the first patient […]
Weekly Digest – July 2025 Weekly Digest – July 2025 08 July 2025: Adagene and ConjugateBio partner to develop novel antibody drug conjugate Adagene has partnered with ConjugateBio to supply a proprietary antibody for use in bispecific ADC development The […]
Weekly Digest – July 2025 Weekly Digest – July 2025 11 July 2025: Lotte Biologics, Abtis collaborate on next-generation ADC technology development Lotte Biologics and Abtis signed an MOU to co-develop next-generation ADC technologies, integrating Abtis’ AbClick linker platform with […]
